.png)
.png)
Arecor featured by the highly regarded industry publication, Scrip - now available for viewing on the Arecor website
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available on the news section of the company’s website via the following link: http://arecor.com/news/
This excellent feature came out shortly after the Company announced that it had filed a Clinical Trial Application (“CTA”) to conduct a Phase I study in Diabetes Type 1 patients of its ultra-rapid acting insulin product, AT247. This novel formulation of prandial insulin is designed to deliver an acceleration of insulin absorption post injection and the filing represents a key and important milestone in the advancement of the Company’s proprietary portfolio for diabetes care.
For more information, please contact:
Dr Sarah Howell
Arecor Limited
Chief Executive officer
Tel: +44 (0) 1223 426060
Email: [email protected]
Mr Tarquin Edwards
Peckwater PR
Mob: +44 (0) 7879 458 364
Email: [email protected]
This excellent feature came out shortly after the Company announced that it had filed a Clinical Trial Application (“CTA”) to conduct a Phase I study in Diabetes Type 1 patients of its ultra-rapid acting insulin product, AT247. This novel formulation of prandial insulin is designed to deliver an acceleration of insulin absorption post injection and the filing represents a key and important milestone in the advancement of the Company’s proprietary portfolio for diabetes care.
For more information, please contact:
Dr Sarah Howell
Arecor Limited
Chief Executive officer
Tel: +44 (0) 1223 426060
Email: [email protected]
Mr Tarquin Edwards
Peckwater PR
Mob: +44 (0) 7879 458 364
Email: [email protected]